Further research by Matthew Ho and his team demonstrated that disabling Histone deacetylase 3 (HDAC3) via knock-out (KO), knock-down (KD), or pharmacological methods in BMSCs reduces myeloma cell proliferation, effectiveness confirmed in patient-derived myeloma cell cultures with BMSCs [35]. Here, HDAC3 is linked to plasma cell myeloma.